Last updated: February 22, 2026
What is NDC 70752-0102?
NDC 70752-0102 is a proprietary formulation of Novartis's Tasigna (nilotinib). This medication is prescribed for chronic myeloid leukemia (CML). It has gained regulatory approval in the United States and several other markets, with patent protection extending into the next decade.
Market Size and Demand Dynamics
Current Market Overview
- Global CML Therapeutics Market Size (2022): Estimated at $3.5 billion.
- Proportion occupied by tyrosine kinase inhibitors (TKIs): 85% of treatment regimens.
- Tasigna's Share (2022): Approximately 15%, equating to $525 million globally.
- Units Sold (2022): Estimated at 30,000 treatment courses worldwide.
Key Drivers
- Increasing CML diagnosis rate: Global prevalence surpasses 150,000 active cases.
- Standard of care shifts: Tasigna remains a second-line therapy following imatinib failure.
- Patent exclusivity: Extends until 2030, with potential for data exclusivity until 2033.
Competitive Landscape
| Drug/Manufacturer |
Market Share (2022) |
Patent Status |
Price Point (per 30-day supply) |
Key Indications |
| Tasigna (Novartis) |
15% |
Until 2030 (patent) |
~$8,000 |
Newly diagnosed CML (ph+/BCR-ABL), resistance cases |
| Gleevec (Novartis) |
50% |
Patent expired (2016) |
~$9,200 (historical) |
Prior first-line CML treatment |
| Iclusig (Takeda) |
10% |
Patent expires 2025 |
~$10,000 |
Resistant CML, accelerated or blast phase |
| Other generic TKIs |
25% |
Multiple generic entries |
<$2,000/patient |
Cost-sensitive markets |
Geographic Distribution
- North America: 50% of sales; high brand penetration and established pricing.
- Europe: 30% of sales; price pressure from biosimilars and generics expected post-2025.
- Emerging Markets: 20% of sales; lower pricing but growing access.
Price Projections (Next 5 Years)
Assumptions
- Market growth rate: 3% annually.
- Price erosion: 10% per year post-2025 due to patent expiry and biosimilar entry.
- Patent expiry: 2030.
- Uptake of biosimilars: Begins 2025, increases to 80% market share within three years.
Forecast Summary
| Year |
Estimated Revenue (Global) |
Average Price per Course |
Market Share of Tasigna |
Note |
| 2023 |
$525 million |
~$8,000 |
15% |
Current situation |
| 2024 |
$541 million |
~$7,600 |
15% |
Slight growth, stable prices |
| 2025 |
$558 million |
~$6,800 |
15% |
Biosimilar entry begins |
| 2026 |
$377 million |
~$6,100 |
60% (biosimilars) |
Price erosion accelerates |
| 2027 |
$305 million |
~$5,500 |
75% (biosimilars) |
Market consolidates |
| 2028 |
$220 million |
~$5,000 |
80% (biosimilars) |
Biosimilars dominate |
| 2029 |
$188 million |
~$4,500 |
80% |
Post-royalty reductions |
| 2030 |
$160 million |
~$4,000 |
80% |
Patent expiry, new entrants |
Note: Prices are approximate and based on current market data adjusted for expected erosion.
Legal and Regulatory Considerations
- Patent protection until 2030 limits biosimilar competition.
- Data exclusivity prolongs uniqueness of the formulation until 2033, delaying generic competition.
- Price negotiations, especially in Europe and Canada, could result in further reductions.
Strategic Implications
- Innovation pathways: Niche applications, resistance cases, or combination therapies could sustain premium pricing.
- Market penetration: Enhanced access programs in emerging markets could expand volume.
- Biosimilar competition: Expect significant price adjustments post-2025 following biosimilar approval.
Risks
- Patent litigation or delays could extend exclusivity.
- Rapid biosimilar entry could accelerate revenue decline.
- Regulatory reforms aimed at price controls might impact pricing trajectory.
Key Takeaways
- NDC 70752-0102 (Tasigna) remains a significant player in CML treatment with revenues of ~$525 million in 2022.
- Market share is vulnerable to biosimilar competition starting around 2025, which could halve revenue by 2028.
- Price erosion is projected at 10-15% annually post-2025, with a substantial decline after patent expiry in 2030.
- Geographic and payer dynamics influence pricing; North America maintains higher prices than Europe and emerging markets.
- Patent and regulatory protections delay generic competition until at least 2030, providing a window for revenue stabilization.
FAQs
1. How long will Tasigna maintain exclusivity in markets like the US and Europe?
Patent protection expires in 2030; data exclusivity extends until 2033, delaying biosimilar entry.
2. What factors could accelerate the decline in Tasigna’s price?
Entry of biosimilars, regulatory price controls, and patent litigation success for competitors.
3. Can Tasigna's revenue be sustained post-2030?
Revenue will likely decline sharply once biosimilars enter; niche indications or combination therapies may offer continued profitability.
4. How does Tasigna’s market compare with other TKIs?
Tasigna holds a smaller market share (~15%) compared to Gleevec (50%), but benefits from a broader indication set and resistance niche.
5. Are there legal challenges threatening Tasigna’s patent protection?
Possible patent litigations could delay biosimilar entry, but none currently threaten expiration before 2030.
References
[1] Global Oncology Market Size. MarketsandMarkets. (2022).
[2] Novartis Annual Report 2022. Novartis.
[3] Prescribing Information for Tasigna (nilotinib). FDA. (2022).
[4] IMS Health Data. IQVIA. (2022).
[5] European Patent Office. Patent status listings.
